Clinical trials: First Line Treatment
Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
This phase III trial compares the effect of adding nivolumab to the usual chemotherapy (cisplatin or carboplatin with gemcitabine) versus standard chemotherapy alone in treating patients with nasopharyngeal cancer that has come…
- Conditions
- Metastatic Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Metastatic Nasopharyngeal Nonkeratinizing Carcinoma, Metastatic Nasopharyngeal Undifferentiated Carcinoma
- Trial name
- NCT04458909
- Testing
- Carboplatin, Cisplatin, Gemcitabine
- Where
- 325 sites in United States, Canada and 2 more
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)
Biliary Carcinoma
Panitumumab Plus Gemcitabine and Oxaliplatin (GEMOX)Versus GEMOX Alone to Treat Advanced Biliary Tract Adenocarcinoma
This is a multi-centre phase II, open-label, randomized (1:1), parallel-arm, study of panitumumab in combination with chemotherapy (P-GEMOX) versus chemotherapy alone (GEMOX).
- Trial name
- Vecti-BIL (NCT01389414)
- Testing
- Panitumumab plus GEMOX chemotherapy, GEMOX chemotherapy
- Where
- 12 sites in Italy
- Volunteers
- 89 people
- Sponsor
- Prof. Massimo Aglietta
Breast Cancer
Bevacizumab and Doxorubicin Hydrochloride Liposome in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00445406
- Testing
- bevacizumab + doxorubin hydrochloride liposme, Bevacizumab
- Where
- Switzerland
- Volunteers
- 43 people
- Sponsor
- Swiss Cancer Institute
Personalized Medicine, Oligometastatic Disease
Feasibility Trial of Darwin OncoTreat and OncoTarget Precision Medicine Testing
This is a feasibility trial to assess use of OncoTarget and OncoTreat testing in a basket design of patients with oligmetastasis across various solid tumor histology.
- Conditions
- Personalized Medicine, Oligometastatic Disease, Feasibility
- Trial name
- NCT06842030
- Testing
- Darwin OncoTarget and OncoTreat
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Good Samaritan Hospital Medical Center, New York
Metastatic Colorectal Cancer
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
This study aimis at detecting the genomic changes of ctDNA in patients of RAS and BRAF wild-type mCRC, who failed after first line treatment containing cetuximab.
- Trial name
- NCT04831528
- Testing
- Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
- Volunteers
- 100 people
- Sponsor
- Fudan University
SCLC, Extensive Stage, Immunotherapy
Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
Immunotherapy combined with chemotherapy has emerged as the standard of care for patients with extensive-stage small cell lung cancer (ES-SCLC). The incorporation of thoracic radiotherapy can enhance treatment efficacy.
- Conditions
- SCLC, Extensive Stage, Immunotherapy, Chemotherapy, Radiotherapy
- Trial name
- NCT06768307
- Testing
- First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Biliary Tract Cancer
The Efficacy and Safety of Nab-paclitaxel Plus S-1 in First-line Treatment of Advanced Biliary Tract Adenocarcinoma
Advanced biliary tract adenocarcinoma has a poor prognosis with limited therapeutic options. Nab-paclitaxel plus S-1 chemotherapy will be given to untreated patients with advanced biliary tract adenocarcinoma for the first-line…
- Trial name
- NCT03830606
- Testing
- Nab-paclitaxel,S-1
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Aiping Zhou
B-cell Lymphoma, Hodgkin Lymphoma
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently…
- Trial name
- CELERITY (NCT06744075)
- Testing
- Blood assessment
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Henri Becquerel
Metastatic Colorectal Cancer
Sunitinib and Capecitabine for First Line Colon Cancer
This study is for patients with metastatic colorectal cancer who have not been treated with chemotherapy for their cancer. The purpose of this study is to find out if Capecitabine and Sunitinib can be used together to improve…
- Trial name
- NCT00961571
- Testing
- sunitinib and capecitabine
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Georgetown University
Advanced or Metastatic Non-Small Cell Lung Cancer
Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
This study is designed to determine the clinical efficacy and toxicity of ABT-869 in combination with carboplatin and paclitaxel in the treatment of subjects with advanced or metastatic NSCLC.
- Trial name
- NCT00716534
- Testing
- ABT-869, Carboplatin, Paclitaxel
- Where
- 37 sites in United States, Australia and 4 more
- Volunteers
- 145 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Lung Cancer
Etoposide and Cisplatin or Carboplatin as First-Line Chemotherapy With or Without Pravastatin in Treating Patients With Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as etoposide, cisplatin, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00433498
- Testing
- carboplatin, cisplatin, etoposide phosphate
- Where
- 86 sites in United Kingdom
- Volunteers
- 846 people
- Sponsor
- University College, London
Breast Cancer
Doxorubicin Hydrochloride Liposome as First-Line Therapy in Treating Older Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as doxorubicin hydrochloride liposome, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00960336
- Testing
- pegylated liposomal doxorubicin hydrochloride
- Where
- France
- Volunteers
- 59 people
- Sponsor
- ARCAGY/ GINECO GROUP
Carcinoma, Adenocarcinoma
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
To estimate the difference in efficacy and safety of bevacizumab and RAD001 compared to bevacizumab and interferon alfa-2a for first-line treatment of patients with metastatic carcinoma of the kidney.
- Conditions
- Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma
- Trial name
- NCT00719264
- Testing
- RAD001(everolimus), interferon alfa-2a, bevacizumab
- Where
- 109 sites in United States, Belgium and 19 more
- Volunteers
- 365 people
- Sponsor
- Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
SYHX2011 in Combination With Carboplatin and Enlonstobart as First-Line Therapy for Squamous Non-Small Cell Lung Cancer
Efficacy and Safety of SYHX2011 Combined with Carboplatin and Enlonstobart versus Nab-Paclitaxel Combined with Carboplatin and Tislelizumab as First-Line Treatment for Squamous Non-Small Cell Lung Cancer
- Trial name
- NCT07662811
- Testing
- SYHX2011, Carboplatin, Enlonstobart
- Volunteers
- 396 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung…
- Trial name
- NCT06217757
- Testing
- Low-dose radiotherapy, Etoposide, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan University
Graft Vs Host Disease
Ibrutinib and Rituxan for Chronic GVHD
This is a phase II trial evaluating the safety and efficacy of the combination of Ibrutinib and Rituximab as primary treatment of chronic GVHD. We plan to enroll 35 patients on this study.
- Trial name
- NCT04235036
- Testing
- Rituximab, Ibrutinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northside Hospital, Inc.
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib
This randomized phase II trial studies how well pemetrexed disodium and carboplatin or cisplatin with or without erlotinib hydrochloride work in treating patients with epidermal growth factor receptor (EGFR) mutant positive stage…
- Trial name
- NCT01928160
- Testing
- pemetrexed disodium, carboplatin, cisplatin
- Sponsor
- Vanderbilt-Ingram Cancer Center
Colorectal Neoplasms, Metastatic Disease
Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer
The purpose of this study is to assess the efficacy and safety of single-agent regorafenib in the first line treatment of frail and/or unfit for polychemotherapy patients with metastatic colorectal cancer (mCRC)
- Trial name
- REFRAME (NCT01875380)
- Testing
- Regorafenib
- Where
- Spain
- Volunteers
- 46 people
- Sponsor
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Metastatic Pancreas Cancer
Durvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)
Research Hypothesis: The combination of ionizing radiation and immunotherapy (durvalumab) is well tolerated and stimulates a clinically significant pancreas-cancer specific immune response.
- Trial name
- Panc-Durval+RT (NCT02885727)
- Testing
- Durvalumab, Radiation Therapy
- Sponsor
- University of Maryland, Baltimore
Non-Small Cell Lung Cancer
A Study to Assess BMS-986207 in Combination With Nivolumab and Ipilimumab as First-line Treatment for Participants With Stage IV Non-Small Cell Lung Cancer
The purpose of this study is to determine the safety and efficacy of BMS-986207 in combination with nivolumab and ipilimumab as first-line treatment for participants with stage IV non-small cell lung cancer (NSCLC).
- Trial name
- NCT05005273
- Testing
- Nivolumab, Ipilimumab, BMS-986207
- Where
- 71 sites in United States, Argentina and 10 more
- Volunteers
- 1 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.